Imatinib (Gleevac) revolutionized treatment for patients with chronic myeloid leukemia (CML). Prior to the drug’s discovery, CML patients generally had seven years to live (possibly less depending on how advanced the cancer was). Now their lifespan mirrors the general population.
I’d highly recommend the book The Philadelphia Chromosome if you’re interested in learning more.
I am currently taking a similar drug for Myelofibrosis on a clinical trial holed up after a stem cell transplant here at MD Anderson Cancer Center. It's called Itacitinib, and is supposed to prevent GVHD. It's by the same company that makes Jakafi (brand name). These are expensive drugs for sure, and my DR is running the clinical trial. Just wanted to chime in from the inside. ;p
BTK inhibitors are technically in 3rd gen (noncovalent) already if you can get in the trials (which are very promising considering they use the same mechanism).
Imatinib (Gleevac) revolutionized treatment for patients with chronic myeloid leukemia (CML). Prior to the drug’s discovery, CML patients generally had seven years to live (possibly less depending on how advanced the cancer was). Now their lifespan mirrors the general population.
I’d highly recommend the book The Philadelphia Chromosome if you’re interested in learning more.
I am currently taking a similar drug for Myelofibrosis on a clinical trial holed up after a stem cell transplant here at MD Anderson Cancer Center. It's called Itacitinib, and is supposed to prevent GVHD. It's by the same company that makes Jakafi (brand name). These are expensive drugs for sure, and my DR is running the clinical trial. Just wanted to chime in from the inside. ;p
Best of luck for your treatment
Car-T seems promising for leukemia and lymphoma, but not as efficacious in solid tumors:
https://www.lls.org/treatment/types-treatment/immunotherapy/...
Also 2nd gen BTK inhibitors:
https://en.wikipedia.org/wiki/Acalabrutinib
https://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase
BTK inhibitors are technically in 3rd gen (noncovalent) already if you can get in the trials (which are very promising considering they use the same mechanism).